Bone Marrow Transplantation News

An ex vivo-expanded umbilical cord blood unit appeared safe and effective as a standalone hematopoietic stem cell graft, shortening time to neutrophil and platelet recovery, according to results of a phase 2 study published in Journal of Clinical Oncology.

Rezafungin dosed concomitantly with other drugs in the treatment of invasive fungal infections in transplant patients resulted in no significant change in systematic concentrations of the “probe drugs,” according to research to be presented at the 2019 Transplantation and Cellular Therapy Meeting.

Roy L. Silverstein, MD, has started his year-long term as president of ASH.

The Center for International Blood and Marrow Transplant Research’s annual report recognized the Fred Hutchinson Cancer Center bone marrow transplant program at Seattle Cancer Care Alliance for better-than-expected 1-year survival rates.

SAN DIEGO — Higher gut microbial diversity was associated with improved survival in a multinational cohort of patients undergoing hematopoietic stem cell transplantation, according to findings presented at ASH Annual Meeting and Exposition.

SAN DIEGO — The addition of a transplant-specific comorbidity score to risk stratification appeared to negate the survival benefit of hematopoietic stem cell transplantation among older patients with acute myeloid leukemia, according to results of a prospective, multicenter, longitudinal study presented at ASH Annual Meeting and Exposition.

SAN DIEGO — A personalized risk prediction model developed using machine learning showed utility as a predictive and prognostic tool among patients with myelodysplastic syndrome, according to findings presented at ASH Annual Meeting and Exposition.

SAN DIEGO — Hematopoietic stem cell transplantation with a sibling donor after reduced-intensity busulfan/fludarabine-based regimen failed to improve outcomes compared with chemotherapy among patients with acute myeloid leukemia in first complete remission, according to results of an intention-to-treat analysis presented at ASH Annual Meeting and Exposition.

SAN DIEGO — Patients with large B-cell lymphoma who experienced progressive disease following anti-CD19 chimeric antigen receptor T-cell therapy had poor long-term outcomes, according to results presented at ASH Annual Meeting and Exposition.

SAN DIEGO — Consolidative hematopoietic stem cell transplant after CD19-directed chimeric antigen receptor T-cell therapy prolonged leukemia-free survival for certain pediatric and young adult patients with relapsed or refractory CD19-positive acute lymphoblastic leukemia, according to results of the PLAT-02 trial presented at ASH Annual Meeting and Exposition.